Put a cork in it: Plugging the M2 viral ion channel to sink influenza

[1]  Chunlong Ma,et al.  Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L , 2020, Science Advances.

[2]  W. DeGrado,et al.  X-ray crystal structures of the influenza M2 proton channel drug-resistant V27A mutant bound to a spiro-adamantyl amine inhibitor reveal the mechanism of adamantane resistance. , 2020, Biochemistry.

[3]  A. Kolocouris,et al.  Spotting Differences in Molecular Dynamic Simulations of Influenza A M2 Protein-Ligand Complexes by Varying M2 construct, Lipid Bilayer and Force Field , 2019 .

[4]  Chunlong Ma,et al.  The L46P Mutant Confers a Novel Allosteric Mechanism of Resistance Toward the Influenza A Virus M2 S31N Proton Channel Blockers , 2019, Molecular Pharmacology.

[5]  W. DeGrado,et al.  X-ray crystal structure of the influenza A M2 proton channel S31N mutant in two conformational states: an open and shut case. , 2019, Journal of the American Chemical Society.

[6]  G. Voth,et al.  Proton Induced Conformational and Hydration Dynamics in the Influenza A M2 Channel. , 2019, Journal of the American Chemical Society.

[7]  J. Torres,et al.  Viroporins in the Influenza Virus , 2019, Cells.

[8]  N. Veljkovic,et al.  Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors , 2019, Front. Cell. Infect. Microbiol..

[9]  A. Monto,et al.  Effects of Influenza Vaccination in the United States during the 2017-2018 Influenza Season. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Chunlong Ma,et al.  Structure-Property Relationship Studies of Influenza A Virus AM2-S31N Proton Channel Blockers. , 2018, ACS medicinal chemistry letters.

[11]  Sehee Park,et al.  Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function , 2018, Journal of Virology.

[12]  K. Lindorff-Larsen,et al.  Random Mutagenesis Analysis of the Influenza A M2 Proton Channel Reveals Novel Resistance Mutants. , 2018, Biochemistry.

[13]  K. Lindorff-Larsen,et al.  A Robust Proton Flux (pHlux) Assay for Studying the Function and Inhibition of the Influenza A M2 Proton Channel. , 2018, Biochemistry.

[14]  W. DeGrado,et al.  Inhibitors of the M2 Proton Channel Engage and Disrupt Transmembrane Networks of Hydrogen-Bonded Waters. , 2018, Journal of the American Chemical Society.

[15]  H. Moriyama,et al.  Influenza D virus M2 protein exhibits ion channel activity in Xenopus laevis oocytes , 2018, PloS one.

[16]  S. Perlman,et al.  Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis , 2018, mBio.

[17]  Chunlong Ma,et al.  Profiling the in vitro drug‐resistance mechanism of influenza A viruses towards the AM2‐S31N proton channel blockers , 2018, Antiviral research.

[18]  Chunlong Ma,et al.  In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. , 2018, Journal of medicinal chemistry.

[19]  J. Lynch,et al.  Divalent copper complexes as influenza A M2 inhibitors , 2017, Antiviral research.

[20]  Benjamin A. Barad,et al.  XFEL structures of the influenza M2 proton channel: Room temperature water networks and insights into proton conduction , 2017, Proceedings of the National Academy of Sciences.

[21]  Chunlong Ma,et al.  Design and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant influenza A viruses. , 2017, European journal of medicinal chemistry.

[22]  L. Naesens,et al.  Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus. , 2017, Journal of medicinal chemistry.

[23]  W. DeGrado,et al.  An M2‐V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine‐sensitive and ‐resistant influenza A viruses , 2017, Antiviral research.

[24]  Chunlong Ma,et al.  Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki-Miyaura Cross-Coupling Reaction. , 2017, Journal of medicinal chemistry.

[25]  Antonios Drakopoulos,et al.  Affinity of Rimantadine Enantiomers against Influenza A/M2 Protein Revisited. , 2017, ACS medicinal chemistry letters.

[26]  Chunlong Ma,et al.  Discovery of Potent Antivirals against Amantadine-Resistant Influenza A Viruses by Targeting the M2-S31N Proton Channel. , 2016, ACS infectious diseases.

[27]  Chunlong Ma,et al.  Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers , 2016, Molecular Pharmacology.

[28]  W. DeGrado,et al.  Crystal structure of the drug‐resistant S31N influenza M2 proton channel , 2016, Protein science : a publication of the Protein Society.

[29]  I. Tietjen,et al.  Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride , 2016, Molecular Pharmacology.

[30]  Ernie Villalon.  Overcoming Challenges , 2016, Progress in transplantation.

[31]  W. DeGrado,et al.  Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel. , 2016, Journal of medicinal chemistry.

[32]  Huan‐Xiang Zhou,et al.  Differential Binding of Rimantadine Enantiomers to Influenza A M2 Proton Channel. , 2016, Journal of the American Chemical Society.

[33]  Zi-feng Yang,et al.  Imidazole-based pinanamine derivatives: Discovery of dual inhibitors of the wild-type and drug-resistant mutant of the influenza A virus. , 2016, European journal of medicinal chemistry.

[34]  A. Kolocouris,et al.  Resistance-Mutation (N31) Effects on Drug Orientation and Channel Hydration in Amantadine-Bound Influenza A M2. , 2015, The journal of physical chemistry. B.

[35]  Luis Carrasco,et al.  Structural and Functional Properties of the Hepatitis C Virus p7 Viroporin , 2015, Viruses.

[36]  Chunlong Ma,et al.  Recent progress in designing inhibitors that target the drug‐resistant M2 proton channels from the influenza A viruses , 2015, Biopolymers.

[37]  Luis Carrasco,et al.  Relevance of Viroporin Ion Channel Activity on Viral Replication and Pathogenesis , 2015, Viruses.

[38]  D. Eggett,et al.  Investigation of a recent rise of dual amantadine-resistance mutations in the influenza A M2 sequence , 2015, BMC Genetics.

[39]  Pascal Amoa Onguéné,et al.  Screening of the Pan-African Natural Product Library Identifies Ixoratannin A-2 and Boldine as Novel HIV-1 Inhibitors , 2015, PloS one.

[40]  Guangju Ji,et al.  Adamantane-Resistant Influenza A Viruses in the World (1902–2013): Frequency and Distribution of M2 Gene Mutations , 2015, PloS one.

[41]  Hans-Joachim Bungartz,et al.  Molecular Dynamics Simulation , 2015 .

[42]  Yamei Gao,et al.  Influenza Virus M2 Protein Ion Channel Activity Helps To Maintain Pandemic 2009 H1N1 Virus Hemagglutinin Fusion Competence during Transport to the Cell Surface , 2014, Journal of Virology.

[43]  R. Lamb,et al.  Flipping in the Pore: Discovery of Dual Inhibitors That Bind in Different Orientations to the Wild-Type versus the Amantadine-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel , 2014, Journal of the American Chemical Society.

[44]  A. Hurt.  The epidemiology and spread of drug resistant human influenza viruses. , 2014, Current opinion in virology.

[45]  A. Helenius,et al.  Stepwise Priming by Acidic pH and a High K+ Concentration Is Required for Efficient Uncoating of Influenza A Virus Cores after Penetration , 2014, Journal of Virology.

[46]  F. J. Luque,et al.  Easily Accessible Polycyclic Amines that Inhibit the Wild-Type and Amantadine-Resistant Mutants of the M2 Channel of Influenza A Virus , 2014, Journal of medicinal chemistry.

[47]  K. Strebel.  HIV-1 Vpu - an ion channel in search of a job. , 2014, Biochimica et biophysica acta.

[48]  A. Herrmann,et al.  pH-Controlled two-step uncoating of influenza virus. , 2014, Biophysical journal.

[49]  James J. Chou,et al.  The minimalist architectures of viroporins and their therapeutic implications , 2013, Biochimica et Biophysica Acta (BBA) - Biomembranes.

[50]  R. Lamb,et al.  3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant. , 2013, Journal of medicinal chemistry.

[51]  G. Moseley,et al.  Bovine Ephemeral Fever Rhabdovirus α1 Protein Has Viroporin-Like Properties and Binds Importin β1 and Importin 7 , 2013, Journal of Virology.

[52]  R. Lamb,et al.  Asp44 stabilizes the Trp41 gate of the M2 proton channel of influenza A virus. , 2013, Structure.

[53]  Dongqing Wei,et al.  Structural and energetic analysis of drug inhibition of the influenza A M2 proton channel. , 2013, Trends in pharmacological sciences.

[54]  Riley J. Payne,et al.  Detection of Proton Movement Directly across Viral Membranes To Identify Novel Influenza Virus M2 Inhibitors , 2013, Journal of Virology.

[55]  R. Lamb,et al.  Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus. , 2013, Journal of medicinal chemistry.

[56]  Huan‐Xiang Zhou,et al.  Modeling the membrane environment has implications for membrane protein structure and function: Influenza A M2 protein , 2013, Protein science : a publication of the Protein Society.

[57]  R. Lamb,et al.  Inhibitors of the Influenza A Virus M2 Proton Channel Discovered Using a High-Throughput Yeast Growth Restoration Assay , 2013, PloS one.

[58]  R. Lamb,et al.  Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus , 2013, Proceedings of the National Academy of Sciences.

[59]  W. DeGrado,et al.  Detection of drug‐induced conformational change of a transmembrane protein in lipid bilayers using site‐directed spin labeling , 2013, Protein science : a publication of the Protein Society.

[60]  M. Casarotto,et al.  Design and synthesis of pinanamine derivatives as anti-influenza A M2 ion channel inhibitors. , 2012, Antiviral research.

[61]  W. DeGrado,et al.  Structural basis for proton conduction and inhibition by the influenza M2 protein , 2012, Protein science : a publication of the Protein Society.

[62]  Huan‐Xiang Zhou,et al.  Recent progress in structure-based anti-influenza drug design. , 2012, Drug discovery today.

[63]  Luis Carrasco,et al.  Viroporins: structure and biological functions , 2012, Nature Reviews Microbiology.

[64]  J. Torres,et al.  The Small Hydrophobic Protein of the Human Respiratory Syncytial Virus Forms Pentameric Ion Channels* , 2012, The Journal of Biological Chemistry.

[65]  S. Petrou,et al.  Viral targets of acylguanidines , 2012, Drug Discovery Today.

[66]  Huan‐Xiang Zhou,et al.  M2 protein from influenza A: from multiple structures to biophysical and functional insights. , 2012, Current opinion in virology.

[67]  Kathy Hancock.  Influenza A Virus , 2020, Definitions.

[68]  J. Chou,et al.  Structural investigation of rimantadine inhibition of the AM2-BM2 chimera channel of influenza viruses. , 2011, Structure.

[69]  J. Englund,et al.  Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[70]  R. Lamb,et al.  Exploring organosilane amines as potent inhibitors and structural probes of influenza a virus M2 proton channel. , 2011, Journal of the American Chemical Society.

[71]  R. Lamb,et al.  Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2. , 2011, Journal of the American Chemical Society.

[72]  Tuo Wang,et al.  Membrane-dependent effects of a cytoplasmic helix on the structure and drug binding of the influenza virus M2 protein. , 2011, Journal of the American Chemical Society.

[73]  Lei Liu,et al.  Free energy calculations on the two drug binding sites in the M2 proton channel. , 2011, Journal of the American Chemical Society.

[74]  F. J. Luque,et al.  Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus. , 2011, Journal of medicinal chemistry.

[75]  Jun Wang,et al.  Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy. , 2011, Journal of the American Chemical Society.

[76]  R. Lamb,et al.  Influenza virus assembly and budding. , 2011, Virology.

[77]  J. V. Van Etten,et al.  Minimal art: or why small viral K(+) channels are good tools for understanding basic structure and function relations. , 2011, Biochimica et biophysica acta.

[78]  Cinque S. Soto,et al.  Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus. , 2011, Current opinion in structural biology.

[79]  J. Chou,et al.  Influenza M2 proton channels. , 2011, Biochimica et biophysica acta.

[80]  Ekta Khurana,et al.  Computational study of drug binding to the membrane-bound tetrameric M2 peptide bundle from influenza A virus. , 2011, Biochimica et biophysica acta.

[81]  L. Gubareva,et al.  Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2011, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[82]  W. Fischer,et al.  Viral channel forming proteins — Modeling the target , 2010, Biochimica et Biophysica Acta (BBA) - Biomembranes.

[83]  T. Hirashita,et al.  Cross-Coupling Reaction , 2011 .

[84]  F. Hayden,et al.  Emerging influenza antiviral resistance threats. , 2011, The Journal of infectious diseases.

[85]  Huan‐Xiang Zhou,et al.  Insight into the Mechanism of the Influenza A Proton Channel from a Structure in a Lipid Bilayer , 2010, Science.

[86]  Mei Hong,et al.  Mechanisms of Proton Conduction and Gating in Influenza M2 Proton Channels from Solid-State NMR , 2010, Science.

[87]  J. Chou,et al.  Solution NMR structure of the V27A drug resistant mutant of influenza A M2 channel. , 2010, Biochemical and biophysical research communications.

[88]  Xianghong Jing,et al.  Influenza Virus M2 Protein Mediates ESCRT-Independent Membrane Scission , 2010, Cell.

[89]  W. DeGrado,et al.  Proton and cation transport activity of the M2 proton channel from influenza A virus , 2010, Proceedings of the National Academy of Sciences.

[90]  Benjamin G. Levine,et al.  Structure and mechanism of proton transport through the transmembrane tetrameric M2 protein bundle of the influenza A virus , 2010, Proceedings of the National Academy of Sciences.

[91]  M. R. Rosenberg,et al.  Coexistence of two adamantane binding sites in the influenza A M2 ion channel , 2010, Proceedings of the National Academy of Sciences.

[92]  James M Aramini,et al.  Structures of influenza A proteins and insights into antiviral drug targets , 2010, Nature Structural &Molecular Biology.

[93]  Y. Okada,et al.  The Human Polyoma JC Virus Agnoprotein Acts as a Viroporin , 2010, PLoS pathogens.

[94]  Benjamin G. Levine,et al.  Functional studies and modeling of pore-lining residue mutants of the influenza a virus M2 ion channel. , 2010, Biochemistry.

[95]  Cinque S. Soto,et al.  Structure of the Amantadine Binding Site of Influenza M2 Proton Channels In Lipid Bilayers , 2010, Nature.

[96]  R. Lamb,et al.  Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. , 2009, Biochemistry.

[97]  Dima Kozakov,et al.  Binding hot spots and amantadine orientation in the influenza a virus M2 proton channel. , 2009, Biophysical journal.

[98]  H. Oshitani,et al.  Large-Scale Sequence Analysis of M Gene of Influenza A Viruses from Different Species: Mechanisms for Emergence and Spread of Amantadine Resistance , 2009, Antimicrobial Agents and Chemotherapy.

[99]  R. Lamb,et al.  Identification of the functional core of the influenza A virus A/M2 proton-selective ion channel , 2009, Proceedings of the National Academy of Sciences.

[100]  Wenbin Luo,et al.  Structure and function of the influenza A M2 proton channel. , 2009, Biochemistry.

[101]  J. Torres,et al.  Structure and Inhibition of the SARS Coronavirus Envelope Protein Ion Channel , 2009, PLoS pathogens.

[102]  W. DeGrado,et al.  Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. , 2009, Journal of the American Chemical Society.

[103]  T. Kamigaki,et al.  Evolution of the M gene of the influenza A virus in different host species: large-scale sequence analysis , 2009, Virology Journal.

[104]  J. Chou,et al.  Mechanism of drug inhibition and drug resistance of influenza A M2 channel , 2009, Proceedings of the National Academy of Sciences.

[105]  Mark A. Miller,et al.  The origin and global emergence of adamantane resistant A/H3N2 influenza viruses , 2009, Virology.

[106]  Christopher J. Oldfield,et al.  Do viral proteins possess unique biophysical features? , 2009, Trends in biochemical sciences.

[107]  S. Cady,et al.  Structure of amantadine-bound M2 transmembrane peptide of influenza A in lipid bilayers from magic-angle-spinning solid-state NMR: the role of Ser31 in amantadine binding. , 2009, Journal of molecular biology.

[108]  Michel Roberge,et al.  Screening for chemical inhibitors of heterologous proteins expressed in yeast using a simple growth-restoration assay. , 2009, Methods in molecular biology.

[109]  E. Carpenter,et al.  Overcoming the challenges of membrane protein crystallography , 2008, Current opinion in structural biology.

[110]  R. Lamb,et al.  The Influenza Virus M2 Protein Cytoplasmic Tail Interacts with the M1 Protein and Influences Virus Assembly at the Site of Virus Budding , 2008, Journal of Virology.

[111]  Xianghong Jing,et al.  Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel , 2008, Proceedings of the National Academy of Sciences.

[112]  J. Chou,et al.  Structure and mechanism of the M2 proton channel of influenza A virus , 2008, Nature.

[113]  Vikas Nanda,et al.  Structural basis for the function and inhibition of an influenza virus proton channel , 2008, Nature.

[114]  N. Cox,et al.  Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. , 2007, The Journal of infectious diseases.

[115]  E. De Clercq,et al.  Influence of an additional 2-amino substituent of the 1-aminoethyl pharmacophore group on the potency of rimantadine against influenza virus A. , 2007, Bioorganic & medicinal chemistry letters.

[116]  R. Lamb,et al.  The M2 Proton Channels of Influenza A and B Viruses* , 2006, Journal of Biological Chemistry.

[117]  N. Cox,et al.  Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. , 2006, JAMA.

[118]  Xiyan Xu,et al.  Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern , 2005, The Lancet.

[119]  P. Gage,et al.  Cation‐selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride , 2004, FEBS letters.

[120]  Menghang Xia,et al.  Automated Electrophysiology Assays -- Assay Guidance Manual , 2004 .

[121]  Charles J. Russell,et al.  Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[122]  R. Lamb,et al.  Influenza B virus BM2 protein has ion channel activity that conducts protons across membranes. , 2003, Developmental cell.

[123]  R. Lamb,et al.  Influenza B virus BM2 protein is an oligomeric integral membrane protein expressed at the cell surface. , 2003, Virology.

[124]  A. Alonso,et al.  The Human Papillomavirus Type 16 E5 Protein Impairs TRAIL- and FasL-Mediated Apoptosis in HaCaT Cells by Different Mechanisms , 2002, Journal of Virology.

[125]  R. Lamb,et al.  The Gate of the Influenza Virus M2 Proton Channel Is Formed by a Single Tryptophan Residue* , 2002, The Journal of Biological Chemistry.

[126]  S. Cinelli,et al.  Effect of the environment on the protein dynamical transition: a neutron scattering study. , 2002, Biophysical journal.

[127]  G. Bodelón,et al.  Modification of Late Membrane Permeability in Avian Reovirus-infected Cells , 2002, The Journal of Biological Chemistry.

[128]  A. Nafziger,et al.  Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. , 2000, Archives of internal medicine.

[129]  J. Denny,et al.  Helix tilt of the M2 transmembrane peptide from influenza A virus: an intrinsic property. , 2000, Journal of molecular biology.

[130]  R. Lamb,et al.  Cu(II) Inhibition of the Proton Translocation Machinery of the Influenza A Virus M2 Protein* , 1999, The Journal of Biological Chemistry.

[131]  R. Lamb,et al.  Influenza C virus CM2 integral membrane glycoprotein is produced from a polypeptide precursor by cleavage of an internal signal sequence. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[132]  R. Webster,et al.  How to overcome resistance of influenza A viruses against adamantane derivatives. , 1998, Antiviral research.

[133]  A Helenius,et al.  Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins , 1996, Journal of virology.

[134]  Luis Carrasco,et al.  Membrane Permeabilization by Poliovirus Proteins 2B and 2BC* , 1996, The Journal of Biological Chemistry.

[135]  A. Hay,et al.  Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells. , 1996, The Journal of physiology.

[136]  R. Lamb,et al.  Characterization of inhibition of M2 ion channel activity by BL-1743, an inhibitor of influenza A virus , 1996, Journal of virology.

[137]  R. Lamb,et al.  Ion selectivity and activation of the M2 ion channel of influenza virus. , 1996, Biophysical journal.

[138]  R. Lamb,et al.  Orthomyxoviridae: The Viruses and Their Replication. , 1996 .

[139]  R. Lamb,et al.  Activation of the M2 ion channel of influenza virus: a role for the transmembrane domain histidine residue. , 1995, Biophysical journal.

[140]  R. Lamb,et al.  Analysis of the posttranslational modifications of the influenza virus M2 protein , 1995, Journal of virology.

[141]  R. Lamb,et al.  Influenza A virus M2 ion channel protein: a structure-function analysis , 1994, Journal of virology.

[142]  R. Lamb,et al.  Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block , 1993, Journal of virology.

[143]  Y. Henis,et al.  Effects of exposure to low pH on the lateral mobility of influenza hemagglutinin expressed at the cell surface: correlation between mobility inhibition and inactivation. , 1993, Biochemistry.

[144]  G. Pugliese,et al.  Severe Streptococcus pyogenes Infections, United Kingdom, 2003–2004 , 2008, Emerging infectious diseases.

[145]  A. Hay,et al.  Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses. , 1992, Virology.

[146]  R. Ashley,et al.  The transmembrane domain of influenza A M2 protein forms amantadine-sensitive proton channels in planar lipid bilayers. , 1992, Virology.

[147]  Lawrence H. Pinto,et al.  Influenza virus M2 protein has ion channel activity , 1992, Cell.

[148]  P. Bayley,et al.  Evidence that the amantadine-induced, M2-mediated conversion of influenza A virus hemagglutinin to the low pH conformation occurs in an acidic trans Golgi compartment. , 1992, Virology.

[149]  K. Martin,et al.  Nuclear transport of influenza virus ribonucleoproteins: The viral matrix protein (M1) promotes export and inhibits import , 1991, Cell.

[150]  A. Douglas,et al.  Specific structural alteration of the influenza haemagglutinin by amantadine. , 1990, The EMBO journal.

[151]  R. Lamb,et al.  Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface , 1985, Cell.

[152]  R. Lamb,et al.  Conservation of the influenza virus membrane protein (M1) amino acid sequence and an open reading frame of RNA segment 7 encoding a second protein (M2) in H1N1 and H3N2 strains. , 1981, Virology.

[153]  R. Lamb,et al.  Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus. , 1981, Virology.

[154]  R. Lamb,et al.  Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[155]  W. G. Laver,et al.  The Influenza Virus Hemagglutinin , 1978, Topics in Infectious Diseases.

[156]  J. A. Snyder,et al.  Antiviral agents. 2. Structure-activity relationships of compounds related to 1-adamantanamine. , 1971, Journal of medicinal chemistry.

[157]  M. Paulshock,et al.  Therapeutic efficacy of amantadine HCl. , 1970, Missouri medicine.

[158]  D. Pollack,et al.  Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. , 1969, The New England journal of medicine.

[159]  R. Young,et al.  Amantadine in the treatment of Parkinson's disease. , 1969, JAMA.

[160]  M. Paulshock,et al.  Antiviral Activity of 1-Adamantanamine (Amantadine) , 1964, Science.